Market research
IPD.AU ImpediMed Limited
AU AUD Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 15M
- P/E ratio
- Not available
- Analyst target
- 0.0209
- Dividend yield
- Not available
- Beta
- 1.07
Profile
Instrument facts
- Exchange
- AU
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Medical Devices
- ISIN
- AU000000IPD8
- Market cap
- 15M
- P/E ratio
- Not available
- Analyst target
- 0.0209
- Dividend yield
- Not available
- Beta
- 1.07
About
About ImpediMed Limited
ImpediMed Limited, a medical technology company, engages in the development, manufacture, and sale of bioimpedance spectroscopy (BIS) systems and software services in Australia, Europe, North America, and internationally. The company offers SOZO Digital Health Platform which transforms fluid status and tissue composition into insights with a single scan; L-Dex Analysis for Lymphedema, designed for early lymphedema detection; BodyComp Analysis; Segmental BodyComp Analysis; and HF-Dex Analysis for Heart Failure. It also provides Lymphedema Prevention Program; and BodyComp Analysis for survivorship health. The company specializes in cancer survivorship, heart health management, medical weight management, wellness, and research. ImpediMed Limited was incorporated in 1999 and is headquartered in Carlsbad, California.
Research context
ImpediMed Limited appears in PyInvesting’s Australia Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Medical Devices
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the IPD.AU discussion.
5 years, 6 months ago
ImpediMed Limited is currently in a long term downtrend where the price is trading 10.3% below its 200 day moving average.
From a valuation standpoint, the stock is 93.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 16.2.
ImpediMed Limited's total revenue rose by 26.2% to $4M since the same quarter in the previous year.
Its net income has increased by 19.3% to $-10M since the same quarter in the previous year.
Finally, its free cash flow grew by 44.5% to $-3M since the same quarter in the previous year.
Based on the above factors, ImpediMed Limited gets an overall score of 4/5.